Stay updated with breaking news from Hematologic Malignancies. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
- Robust immune response with clinical activity at the highest dose level with one patient achieving no evidence of disease 7 months post-infusion with NEXI-001 ... | June 5, 2023
Real-World Results Demonstrate Objective Response Rate of 67% in 24 EBV+ PTLD Patients 91% Overall Survival at One Year for Patients Responding to Tab-cel Compared to 34% for... | June 5, 2023
/PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to...
Dublin, June 01, 2023 (GLOBE NEWSWIRE) -- The "Global T-Cell Immunotherapy Market (2023-2028) by Therapy Type, Mechanism of Action, Product Class,...
/PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced an upcoming poster presentation highlighting the Company's IRAK1/4 program at the...